首页> 美国政府科技报告 >Lycopene Supplementation in the Complementary Management of PSA Failure: A Randomized Placebo-Controlled Trial for Prostate Cancer Survivors
【24h】

Lycopene Supplementation in the Complementary Management of PSA Failure: A Randomized Placebo-Controlled Trial for Prostate Cancer Survivors

机译:psa失败的补充管理中的番茄红素补充:前列腺癌幸存者的随机安慰剂对照试验

获取原文

摘要

This is a hypothesis driven, double-blind, randomized, controlled Phase II clinical trial to compare the effect of daily 12-month supplementation of 30mgs lycopene as a single nutrient (Lycopene) or whole-food supplement (Lyc- O-Mato(Registered)) in control of biochemical (PSA) failure in 78 African- American prostate cancer survivors treated initially by radical prostatectomy or radiation. Fasting blood samples to measure free and total PSA, lycopene, isoprostane and essential fatty acids will be collected at baseline, 3- 6- and 12-months. Demographic and medical history, clinical and quality of life (QOL) assessment, dietary assessment, body fat measures and adverse event information will be collected at baseline and all follow-up time-points. Clinical endpoints are >50% PSA reduction from baseline maintained for 2 successive readings 3 months apart, >25% improvement in QOL scores, and control of distant metastasis. Biomarker endpoints are changes in plasma lycopene, and 8- isoprostane-PGF2alpha, a measure of oxidative stress. The effect of the interventions will be analyzed based on evaluable patients as well as by intent- to-treat.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号